Benjamin L. Judson MD

Assistant Professor of Surgery (Otolaryngology); Associate Residency Program Director, Otolaryngology; Medical Director, Ambulatory Clinics, Smilow Cancer Hospital at Yale-New Haven

Specialties & Subspecialties

Cancer Center, Yale: Head and Neck Cancer Surgery Program

Surgery: Otolaryngology: Head and Neck Cancer Services

Education & Training

  • B.A., Middlebury College (1991)
  • M.P.A., University of Pennsylvania (1995)
  • M.D., Jefferson Medical College (2002)
  • Resident, Georgetown University Hospital , Otolaryngology
  • Administrative Chief Resident, Georgetown University Hospital , Otolarynogology - Head & Neck Surgery
  • Research Fellow, Weill Cornell Medical College , Medicine
  • Fellow, Memorial Sloan-Kettering Cancer Center , Head & Neck Surgery

Patient Care

Accepts New Patients? Yes | Patient Type: Adult, Adolescent, Child, Geriatric | Accepts referrals from patients


Clinical Interests

oral cavity tumors; pharynx and larynx tumors; salivary tumors; skin cancers; thyroid tumors; sinonasal and skull base tumors; head and neck surgery


Board Certifications

  • Otolaryngology, Board Certified (2008)

Clinical Trials

ConditionsStudy Title
Brain and Nervous System and Other Respiratory and Intrathoracic OrgansA randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients with stage III, IVa, or IVb loco-regionally advanced head and neck squamous cell carcinoma
Unknown SitesNovel Treatment to Enhance Smoking Cessation before Cancer Surgery
A Window Study to assess the activity of demethylation therapy in patients with HPV positive compared with HPV negative Head and Neck Squamous Cell Carcinoma
StomachMK-3475-040-00: A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer
Lip, Oral Cavity and PharynxECOG 3311: Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

Edit Profile